Drugs / IL-22
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07060638 Comparator | Jan 2026 → Dec 2029 expected | alcoholic hepatitis | Samer Gawrieh | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07060638 ↗ |
| Modality | Protein / enzyme biologic | “fusion protein of human IL-22 with IgG2 fragment” NCT07060638 ↗ |